Form 4: Viracta Therapeutics Director Roger Pomerantz Reports Stock Transaction
SEC Form 4 Filing
Director Roger Pomerantz reports the disposition of 9,035 common stock shares to satisfy vesting restricted stock units.
Summary
- On May 25, 2024, Roger Pomerantz, a director of Viracta Therapeutics, Inc., reported a transaction involving the company's common stock.
- Pomerantz disposed of 9,035 shares of common stock.
- This transaction was related to the vesting of restricted stock units (RSUs).
- Following the transaction, Pomerantz directly owns 108,410 shares of Viracta Therapeutics, Inc.
- Pomerantz also holds 36,137 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.
Industry Context
This is a standard Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/25/2024 | Date of transaction involving common stock and restricted stock units. |
| 05/28/2024 | Date of Power of Attorney execution. |
| 05/29/2024 | Date of signature for the report. |
Keywords
Viracta Therapeutics, Roger Pomerantz, Form 4, Stock Transaction, Director, Restricted Stock Units, VIRX, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.